Helicobacter pylori에 대한 항균활성을 나타내는 Pediococcus pentosaceus CBT SL4 배양물의 감염방어 및 제균활성

Protection of Infection and Eradication Activity of Culture Product by Pediococcus pentosaceus CBT SL4 Showing Antimicrobial Activity against Helicobacter pylori

  • Hong, Un-Pyo (Cellbiotech R&D Center, Department of Biological Engineering and Center for Advanced Bioseperation Technology, Inha University) ;
  • Chung, Myung-June (Cellbiotech R&D Center) ;
  • Kim, Soo-Dong (Cellbiotech R&D Center) ;
  • Oh, Eun-Taex (Department of Biological Engineering and Center for Advanced Bioseperation Technology, Inha University) ;
  • So, Jae-Seong (Department of Biological Engineering and Center for Advanced Bioseperation Technology, Inha University) ;
  • Chung, Chung-Il (Animal Husbandry College, Konkuk University)
  • 발행 : 2004.10.31

초록

P. pentosaceus CBT SL4균이 생산하는 항균물질 농축건조물은 H. pylori균에 대하여 평판 및 액상배양 조건에서 생육억제 활성이 확인되었고, 사막모래쥐를 사용한 감염실험에서는 감염방어 및 제균작용이, 보균자 인체실험에서는 제균작용이 확인되었다. 최근 3제 요법이나 신규 약물 등에 의하여 자각증세가 있는 위염증 환자에서의 제균율은 크게 향상되었으나, 국내의 경우에는 전체국민의 감염율이 매우 높은 것과 식습관 등의 요인에 의하여 단체 및 사회생활을 통한 신규감염이나 재감염을 방어할 효과적 수단은 없는 상태에 있다. 따라서, 일상적인 섭취가 가능하고, 병원균의 내성개발 우려나 인체에 대한 부작용이 없으며, H. pylori균에 대한 감염방어 및 제균작용을 동시에 지닌 유산균 및 그 항균활성물질을 이용한 식품소재는 국민전체의 H. pylori 감염율을 낮추고, 신규감염과 재감염의 악순환을 방지하기 위한 유용한 방어수단이 될 수 있을 것으로 판단된다. 한편, 유산균 배양액에 의한 H. pylori균에 대한 생육억제 현상은 모든 유산균에서 보편적인 현상은 아닌 것으로서 특정한 균주의 배양액에서만 관찰되고 있어 단순히 젖산 등 유기산에 의한 효과로 보기에는 어려움이 있으며 Gram 음성의 병원균들은 외막의 보호작용에 의하여 분자량이 큰 박테리오신 성분에 의해서는 생육이 억제되지 않는 것으로 판단되고 있다. 저자들은 당 균주가 생성하는 H. pylori 생육 억제 물질을 산성의 저분자 물질로 추정하고, 물질 및 작용기작 규명을 위하여 활성물질의 분리 및 구조분석 작업을 진행 중에 있으며, 이러한 연구가 완료되면 분리정제 물질을 활용한 추가적인 산업화 용도 개발이 가능할 것으로 기대하고 있다.

New food ingredient was developed to eradicate and protect against re-infection of Helicobacter pylori in fermentation broth of lactic acid bacteria (LAB) showing antimicrobial activity against pathogenic microorganisms such as H. pylori and Listeria monocytogenes. LAB strain CBT SL4 was identified as Pediococcus pentosaceus by 16S rDNA sequencing and its culture broth showed antimicrobial activity of 800 AU/mL against H. pylori in optimized fermentation process. Using thin layer concentration system and spray-typed fluid bed drier system, concentrated powder product showing activity of 12,800 AU/g was harvested. Product showed eradication and protection activities against H. pylori infection on feeding test (50 AU/day) using Mongolian gerbil infection model. After 4 weeks therapy of 8,000 AU/day, ${\Delta}13CO_2$ level (DOB30) decreased about 40% in urea breath test on patient with H. pylori infection. Result show concentrated culture product of P. pentosaceus CBT SL4 has eradicating and protecting activities against H. pylori infection and can be used as food-active ingredient for prevention of gastric and duodenum ulcer caused by H. pylori.

키워드

참고문헌

  1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. J. Clin. Microbiol. Rev.10: 720-741 (1997)
  2. Roe IH, Yang MR, Kim JT, Joe JH, Lee JH. Ammonia induced gastric mucosal injury: Role of ammonia in the mechanism of Helicobacter pylori-related gastric disease. J. Korean Gastroenterol. 29: 442-448 (1997)
  3. Jang BK, Ahn SH, Hu JW, Hwang JS, Kang YW, Park SK. The effect of Helicobacter pylori infection on peptic ulcer bleeding. J. Korean Gastroenterol. 34: 295-300 (1999)
  4. Yi JS, Kwon KS, Hong ES, Shin HJ, Park YJ, Cho HG, Kim PS, Lee DH, Choi W, Shin YW, Kim YS. Correlation between hyperammonemia and gastric Helicobacter pylori infection in patients with liver cirrhosis. J. Korean Gastroenterol. 34: 338-344 (1999)
  5. Koga Y. Helicobacter pylori association with gastric disease including gastric cancer. J. Korean Public Health Assoc. 27: 177- 180 (2001)
  6. Shirota T. Helicobacter pylori infection and severity of reflux esopagitis. Jpn. Pharmacol. Ther. 25: 55-59 (1997)
  7. Miyagawa N. Effects of butyric acid bacteria on the loose stools of the Helicobacter pylori eradication. Jpn. Pharmacol. Ther. 27: 59-63 (1999)
  8. Ha KY. Recent trend of Helicobacter pylori infection. J. Korean Soc. Chemother. 16: 307-325 (1998)
  9. Ree KH, Youn HS, Baik SC, Lee WK, Cho MJ, Choi HJ, Maeng KY, Ko KW. Prevalence of Helicobacter pylori infection in Korea. J. Korean Soc. Microbiol. 25: 474-490 (1990)
  10. Baik SC, Kim JB, Cho MJ, Kim YC, Park CK, Ryou HH, Choi HJ, Lee KH. Prevalence of Helicobacter pylori infection among normal Korean adults. J. Korean Soc. Microbiol. 25: 455-462 (1990)
  11. Koo JK, Choe TB, Studies on adherance inhitition and detachment of Helicobacter pylori using egg yolk IgY and additives. Korean J. Biotechnol. Bioeng. 16: 41-47 (2001)
  12. Kim BJ, Kang BH, Kim TY, Kim TH, Kim KW. Production and characterization of IgY specific to Helicobacter pylori. Korean J. Appl. Microbiol. Biotechnol. 25: 612-616 (1997)
  13. Koo JK, Kim CH, Choe TB. Inhibition of growth and adhesion of Helicobacter pylori using egg yolk antibodies. Biotechnol. Bioprocess Eng. 4: 219-223 (1999) https://doi.org/10.1007/BF02931933
  14. Servin AL. Antagonistic activity against Helicobacter pylori infection by the lactic acid bacteria. J. Korean Pubic Health Assoc. 27: 5-12 (2001)
  15. Lee YH, Shin EJ, Lee JH, Park JH, Lactobacillus acidophilus inhibits the Helicobacter pylori adherence. J. Microbiol. Biotechnol. 9: 794-797 (1999)
  16. Jung HC, Effect of fermented milk on the Helicobacter pylori infection in human stomach mucous. J. Korean Public Health Assoc. 27: 193-197 (2001)
  17. Won BR, Song EH, Kang GH, Chang MW. Yoon YH. Inhibitory effect of Lactobacillus helveticus CU 631 on urease and vacuolating toxin activity of Heliobacter pylori. J. Korean Anim. Sci. Technol. 43: 931-940 (2001)